

 MATINS HEALTHCARE PVT. LTD.		MATINS HEALTHCARE PVT. LTD. PLOT No - 10, SEC TOR-5, IIE, SIDCUL, HARIDWAR Mfg. Licence No.: 61/UA/SC/P-2006 & 62/UA/2006	
		QUALITY CONTROL DEPARTMENT (FINISHED) (The Drugs & Cosmetics Act 1940 and the Rules there under)	
CERTIFICATE OF ANALYSIS			
Product Name	HEALMARYL MV 1.3	A.R. No.	MFGT-231279
Generic Name	Metformin HCl (SR), Glimepiride & Voglibose Tablets	Batch Size	1.0 Lac Tablets
Batch No.	MT-231279	Sample Qty.	100 Tablets
Mfg. Date	10/2023	Sample received date	21/11/2023
Exp. Date	09/2025	Date of Release	22/11/2023
Sr. No.	TESTS	SPECIFICATIONS	RESULTS
1	Description	Yellow/White colour elongated, biconvex, uncoated bilayer tablets	Yellow/White colour elongated, biconvex, uncoated bilayer tablets
2	Identification: By HPLC	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	Complies
3	Average weight	860 mg $\pm$ 5% (817.0 to 903.0 mg)	859.10 mg
4	Uniformity of weight	$\pm$ 5% on average weight	Positive deviation= 1.34% Negative deviation= 1.49%
5	Uniformity of content for Glimepiride	NLT 85% to NMT 115%	95.79% to 102.36%
6	Uniformity of content for Voglibose	NLT 85% to NMT 115%	96.63% to 103.82%
7	Dissolution for Metformin Hydrochloride After 1 st hour After 3 rd hour After 10 th hour	(NMT 40%) (45% to 75%) (NLT 85%)	(34.01% to 38.22%) (62.30% to 73.81%) (91.59% to 98.20%)
8	Assay: Each uncoated bilayer tablet contains:		
	Metformin Hydrochloride IP 500 mg (As Sustained release)	Not less than 90% and not more than 110% (450.0 mg to 550.0 mg)	514.57 mg (102.91%)
	Glimepiride IP 1 mg	Not less than 90% and not more than 110% (0.9 mg to 1.1 mg)	1.01 mg (101.00%)
	Voglibose IP 0.3 mg	Not less than 90% and not more than 110% (0.27 mg to 0.33 mg)	0.305 mg (101.67%)
Remarks: The product complies as per IHS Specification.			
 22/11/2023 Analyzed by		 22/11/2023 Checked by	
		 Approved by	